PURPOSE: The predictive value of (18)F-FDG PET in patients with relapsing/refractory lymphoma who are receiving high-dose chemotherapy and autologous stem cell transplantation(ASCT) remains a matter of debate. Seminal reports on pretransplant ASCT indicated an adverse prognosis in patients with positive FDG PET scans. The lack of a uniform outcome measure along with the mixed histologies in various studies have hampered efforts to quantify this prognostic value. METHODS: A MEDLINE review of published trials up to April 2009 identified 16 studies involving pretransplant FDG PET scans in lymphoma. Where progression-free survival (PFS) and overall survival (OS) were set as themain outcome measures, time-to-event data analysis was used to calculate the overall prognostic value of a pretransplant FDG-PET scan. RESULTS: Pooled survival data from seven eligible studies suggested a worse PFS in patients with a positive FDG PET study (HR 3.23, 95% CI 2.14 to 4.87). The OS pooled from six eligible studies was also significantly worse among patients with a positive FDG PET study (HR 4.53, 95%CI 2.50 to 8.22). No statistically significant heterogeneity was observed between studies for either outcome. CONCLUSION: Despite the documented clinical heterogeneity between studies, meta-analysis data confirmed the prognostic impact of pretransplant FDG PET in patients with lymphoma and provided a uniform measure of the association for both progression and survival after ASCT.
PURPOSE: The predictive value of (18)F-FDG PET in patients with relapsing/refractory lymphoma who are receiving high-dose chemotherapy and autologous stem cell transplantation(ASCT) remains a matter of debate. Seminal reports on pretransplant ASCT indicated an adverse prognosis in patients with positive FDG PET scans. The lack of a uniform outcome measure along with the mixed histologies in various studies have hampered efforts to quantify this prognostic value. METHODS: A MEDLINE review of published trials up to April 2009 identified 16 studies involving pretransplant FDG PET scans in lymphoma. Where progression-free survival (PFS) and overall survival (OS) were set as themain outcome measures, time-to-event data analysis was used to calculate the overall prognostic value of a pretransplant FDG-PET scan. RESULTS: Pooled survival data from seven eligible studies suggested a worse PFS in patients with a positive FDG PET study (HR 3.23, 95% CI 2.14 to 4.87). The OS pooled from six eligible studies was also significantly worse among patients with a positive FDG PET study (HR 4.53, 95%CI 2.50 to 8.22). No statistically significant heterogeneity was observed between studies for either outcome. CONCLUSION: Despite the documented clinical heterogeneity between studies, meta-analysis data confirmed the prognostic impact of pretransplant FDG PET in patients with lymphoma and provided a uniform measure of the association for both progression and survival after ASCT.
Authors: Karoline Spaepen; Sigrid Stroobants; Patrick Dupont; Peter Vandenberghe; Johan Maertens; Guy Bormans; José Thomas; Jan Balzarini; Christine De Wolf-Peeters; Luc Mortelmans; Gregor Verhoef Journal: Blood Date: 2003-02-27 Impact factor: 22.113
Authors: U Cremerius; U Fabry; J E Wildberger; M Zimny; P Reinartz; B Nowak; W Schaefer; U Buell; R Osieka Journal: Bone Marrow Transplant Date: 2002-07 Impact factor: 5.483
Authors: Amin M Alousi; Rima M Saliba; Grace-Julia Okoroji; Homer A Macapinlac; Chitra Hosing; Martin Korbling; Barry I Samuels; Uday Popat; Partow Kebriaei; Paolo Anderlini; Muzaffar H Qazilbash; Marcos de Lima; Sergio A Giralt; Richard E Champlin; Issa F Khouri Journal: Br J Haematol Date: 2008-06-17 Impact factor: 6.998
Authors: J Svoboda; C Andreadis; R Elstrom; E A Chong; L H Downs; A Berkowitz; S M Luger; D L Porter; S Nasta; D Tsai; A W Loren; D L Siegel; E Glatstein; A Alavi; E A Stadtmauer; S J Schuster Journal: Bone Marrow Transplant Date: 2006-06-12 Impact factor: 5.483
Authors: S Bishu; J M Quigley; J Schmitz; S R Bishu; R A Stemm; S M Olsasky; S Paknikar; K H Holdeman; J O Armitage; J H Hankins Journal: Leuk Lymphoma Date: 2007-08
Authors: Veronika Bachanova; Linda J Burns; Kwang Woo Ahn; Ginna G Laport; Görgün Akpek; Mohamed A Kharfan-Dabaja; Taiga Nishihori; Edward Agura; Philippe Armand; Samantha M Jaglowski; Mitchell S Cairo; Amanda F Cashen; Jonathon B Cohen; Anita D'Souza; César O Freytes; Robert Peter Gale; Siddhartha Ganguly; Nilanjan Ghosh; Leona A Holmberg; David J Inwards; Abraham S Kanate; Hillard M Lazarus; Adriana K Malone; Reinhold Munker; Alberto Mussetti; Maxim Norkin; Tim D Prestidge; Jacob M Rowe; Prakash Satwani; Tanya Siddiqi; Patrick J Stiff; Basem M William; Baldeep Wirk; David G Maloney; Sonali M Smith; Anna M Sureda; Jeanette Carreras; Mehdi Hamadani Journal: Biol Blood Marrow Transplant Date: 2015-05-14 Impact factor: 5.742
Authors: Craig S Sauter; Lauren Lechner; Michael Scordo; Junting Zheng; Sean M Devlin; Stephen E Fleming; Hugo Castro-Malaspina; Craig H Moskowitz Journal: Biol Blood Marrow Transplant Date: 2014-02-15 Impact factor: 5.742